Advemto Ltd. Information

Drug candidates are generated faster than they can be tested. Libraries can exceed a million variants but function is still measured using arrayed assays a few hundred of a thousand wells at a time. AI widens the gap by designing more candidates, not fewer. Advemto closes that gap. Advemto's proprietary technology enables testing the entire candidate library all at once in a mixed pool, which is then unmixed to precisely pair observations of cell behavior with their programming. Our customers are the discovery teams inside biotechnology and pharmaceutical companies who design antibodies and cell therapies, where hit generation and optimisation absorb roughly half of discovery research budgets. The plate is a consumable. No new instruments required. Advemto is a Seed stage company headquartered in Wellington, New Zealand.